HCPLive’s Post

View organization page for HCPLive, graphic

3,711 followers

7mo

#ACC24 Spotlight: Data from the IMPROVE-HCM trial, presented by Martin S. Maron, MD, of Lahey Hospital & Medical Center, offer hope for patients with nonobstructive HCM, as results of the phase 2 trial suggest use of ninerafaxstat, a cardiac mitotrope from Imbria Pharmaceuticals, was well-tolerated and improved exercise capacity among patients with nonobstructive hypertrophic cardiomyopathy. Check out our coverage here: https://lnkd.in/eJfG2y6q #Cardiomyopathy #Cardiology

Transcript

So improve HCM is the study evaluating the nerfs and it's a phase two study, OK, which means that it was predominant. The predominant goal is really to look first and foremost at safety and tolerability of the drug. But as well we looked at a number of different clinical efficacy measures including that of exercise capacity by cardio pulmonary exercise test and also heart failure symptoms, OK, as measured by Kansas City heart failure questionnaire. OK. And So what we found was first and foremost that the near fax that in a population of non obstructive HCM patients and by the way the population of patients that we were looking at in order to be in the trial, you had to have that objective evidence of exercise limitation. OK. So less than 80% of for peak VO2, OK. So within that kind of symptomatic non official population, what we found was that in the near fax that first and foremost was very well tolerated, OK and the and and and therefore generally safe, OK. In terms of clinical efficacy, what we found was that first and foremost is that Niner Fax had improved exercise capacity. As measured by ventilatory efficiency. So there was an improvement in the cardio pulmonary exercise variable of ventilatory efficiency that was enhanced with linear fax at compared to placebo. Demonstrating that the near facts that had him was able to improve the performance of exercise in patients with non obstructive HCM. Yeah. And the second big thing is well about the comment that is that is that for those patients that were most limited by symptoms at baseline treatment within near fax ad improved symptoms in those patients by demons by demonstrating an improved a significant improvement in the KC score of of. Of nine points essentially OK, with five with a change by the way of five points usually considered to be clinically meaningful. OK. So essentially kind of summarize it up near facts that well tolerated. But as well demonstrated improvement in exercise capacity and also an improvement in symptoms.

To view or add a comment, sign in

More Relevant Posts

Greg Rossi

Account Manager – BioPharma Division at Citeline
1mo
Report this post
🚀 Edgewise Therapeutics' Cardiomyopathy Data Shows Blockbuster Potential 💥💊 Edgewise Therapeutics has unveiled impressive early results for EDG-7500, a novel treatment for obstructive hypertrophic cardiomyopathy (oHCM) 💓. Following the data release, the company’s share price surged by two-thirds 📈, now at $29.50, with analysts projecting peak sales of $2 billion 💰 by the mid-2030s, pending approval. The Phase I trial showed a clean safety profile 🧬, and the Phase II CIRRUS-HCM trial demonstrated promising heart function improvements 🫀. EDG-7500 could be a game-changer 🎯 for those with oHCM, and we’re eager to see what’s next. #Cardiomyopathy #Biotech #Pharma #Citeline #oHCM #clinicaltrials #Cardiology
Like Comment
To view or add a comment, sign in
Luis Sanchez-Velazquez.

Medical Director
9mo
Report this post
CARDIOVASCULAR. Effects of nebivolol therapy on hemodynamic parameters and lipid profile. Dr. David. #director #gerente #farma #industriafarmaceutica #industriafarmacéutica #pharma #bigpharma #nebivolol #cardiologia
Like Comment
To view or add a comment, sign in
Diwakar Gupta

a healthcare imaging expert at AIIMS Delhi with R&D enthusiasm using AI and ML
1mo
Report this post
PET Mycardial Perfusion Imaging for the detection of Coronary Artery Disease will be far better than the current modalities we are using till now.. It will open a new era in #CardiacImaging .
Peter J Arduini

President & CEO at GE HealthCare
1mo

I am thrilled to share an exciting announcement from our Pharmaceutical Diagnostics business - the FDA has approved GE HealthCare's Flyrcado™ (flurpiridaz F 18) injection in the US, a first of its kind positron emission tomography myocardial perfusion imaging (PET MPI) agent, for the detection of coronary artery disease (CAD) – the most common type of heart disease. This milestone achievement has the potential to expand clinician and patient access to PET MPI. It is an important moment in molecular imaging as we continue our journey to address unmet patient needs and advance more precise, personalized care. Learn more about this announcement in our press release: https://lnkd.in/eah2zxyk. Select Important Safety Information Adverse Reactions • Most common adverse reactions occurring during FLYRCADO PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Find here the full prescribing information: https://lnkd.in/esE7VVKX #GEHealthCare #radiopharma #precisioncare
Like Comment
To view or add a comment, sign in
bioSeedin

5,562 followers
2mo
Report this post
𝐁𝐚𝐲𝐞𝐫'𝐬 𝐊𝐄𝐑𝐄𝐍𝐃𝐈𝐀® 𝐒𝐡𝐨𝐰𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐏𝐡𝐚𝐬𝐞 𝐈𝐈𝐈 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐏𝐚𝐭𝐢𝐞𝐧𝐭𝐬 𝐰𝐢𝐭𝐡 𝐇𝐞𝐚𝐫𝐭 𝐅𝐚𝐢𝐥𝐮𝐫𝐞 𝐚𝐧𝐝 𝐋𝐕𝐄𝐅 ≥𝟒𝟎% New data from the Phase III FINEARTS-HF trial presented at ESC Congress 2024 and published in NEJM reveal KERENDIA® (finerenone) significantly reduces cardiovascular death and heart failure (HF) events in patients with HF and LVEF ≥40%. KERENDIA is the first non-steroidal mineralocorticoid receptor antagonist (MRA) to achieve this milestone. The study showed a 16% reduction in the composite of cardiovascular death and HF events, with safety signals consistent with previous trials. Bayer plans to discuss this data with the FDA for potential regulatory approval. #HeartFailure #Cardiology #ClinicalTrials #ESC2024 #Pharma #Biopharma #Cardiovascular #FDA #DrugDevelopment
Like Comment
To view or add a comment, sign in
Aman Alok

Digital Health
4w
Report this post
I’m thrilled to announce that Carelog has received FDA Breakthrough Device Designation for our innovative ECG algorithm that detects diastolic dysfunction—an often underdiagnosed precursor to heart failure with preserved ejection fraction (HFpEF). Early detection is critical, as HFpEF patients face significant challenges: current treatment options are limited, mostly pharmaceutical, and the 5-year survival rate for these patients can range from 40% to 60%. Our AI-powered ECG solution provides a non-invasive, accessible method to detect diastolic dysfunction early, potentially enabling clinicians to intervene sooner and improve patient outcomes. By offering an alternative to costly and complex imaging methods like echocardiography, we hope to change the way HFpEF is managed, giving patients a better chance at long-term survival. A huge thank you to our incredible team and partners for their dedication and innovation. We’re excited to continue pushing the boundaries of cardiovascular care! #FDA #breakthrough #healthtech #ECG #cardiology #AI #diastolicdysfunction #HFpEF #earlydiagnosis #medicaldevice #innovation

31 Comments
Like Comment
To view or add a comment, sign in
Statpedia

6,093 followers
9mo
Report this post
Microcatheters Market | Grows at CAGR of 5.5% by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞-https://lnkd.in/dp8UzkQu The global microcatheters market in terms of revenue was estimated to be worth $874 million in 2023 and is poised to reach $1,142 million by 2028, growing at a CAGR of 5.5% from 2023 to 2028. Boston Scientific Medtronic Terumo Medical Corporation Johnson & Johnson Cook Medical Abbott BKK B. Braun Melsungen AG Cardinal Health Becton, Dickinson and Company Teleflex Stryker Merit Medical Systems, Inc. MicroVention-Terumo Zeus Industrial Products, Inc. Biomerics Integra LifeSciences Penumbra, Inc. Sequent Medical Nitiloop Ltd. Medyria Oxford Endovascular Ltd. Centerline Biomedical Revascular Therapeutics Perfusion Tech GVMED DISTRIBUIDORA DE MEDICAMENTOS Beacon Endoscopic Agilent Technologies
Like Comment
To view or add a comment, sign in
Kaan Pazarkoylu

Biomedical Engineering Technologist
1mo
Report this post
Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain NEW YORK--(BUSINESS WIRE)--Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01). The Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) enrolled 417 patients at 30 investigational sites across the U.S., in a two-year period. SB-01 is the first intradiscal pha via Business Wire Health: Medical Devices News
Like Comment
To view or add a comment, sign in
Jordan Moretti

Connecting marketers with HCPs through medical media
6mo Edited
Report this post
ICYMI 🔊 Now that the dust has settled, here are 5 of the biggest updates from the American College of Cardiology Annual Scientific Sessions, brought to you by HCPLive -Christie Ballantyne MD on the SHASTA-2 trial and plozasiran (Arrowhead Pharmaceuticals) in severe hypertriglyceridemia -Martin S. Maron, MD on the IMPROVE-HCM trial and ninerafaxstat (Imbria Pharmaceuticals) for nonobstructive hypertrophic cardiomyopathy (HCM) (1:40) -Sara Saberi, MD on recent advancement in pharmacotherapy within the management of HCM (4:10) -Javed Butler for a breakdown of the EMPACT-MI trial (Boehringer Ingelheim) (6:40) -Deepak L. Bhatt, MD, MPH, MBA with a recap of top trials and new data at ACC 2024, including the DanGer Shock trial (Abiomed) (10:35) #cardiology
Like Comment
To view or add a comment, sign in
Neuronano AB

323 followers
9mo
Report this post
Neuronano is pioneering in highly specific Deep Brain Stimulation (DBS) therapy. We do this by optimizing the implantation process in addition to utilizing a controlled array of super thin electrodes that can be individually controlled. Neuronano’s DBS offers personalized therapy for Parkinson’s, tailored to the unique needs of each patient, with limited side effects. Normally, pharmaceutical care for Parkinson's disease, employing medications like levodopa and dopamine agonists, offers symptom relief but poses risks due to potential side effects. Common adverse reactions include dyskinesias, nausea, hallucinin compations, and motor fluctuations. Prolonged use, especially of levodopa, may lead to cognitive issues. Read more about our research at https://lnkd.in/gtm45A7
Like Comment
To view or add a comment, sign in

HCPLive

3,711 followers

View Profile Follow

More from this author

Explore topics

翻译：